Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
Info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

November 06, 2026

To,
THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
NSE SYMBOL: INFINIUM

Dear Sir/Madam,

Sub: Submission of Unaudited Financial Results for the Half Year ended September 30, 2026, (Standalone and Consolidated) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we hereby submit the Unaudited Financial Results of the Company (Standalone and Consolidated) with Limited Review Report for the half year ended September 30, 2026, duly approved by the Board of Directors at its meeting held on November 06, 2026.

The following documents are enclosed herewith:

- Outcome of Board Meeting as per Regulation 30 and other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- Statement of Unaudited Financial Results (Standalone) for the half year ended September 30, 2026 with Limited Review Report issued by the Auditors of the Company.
- Statement of Unaudited Financial Results (Consolidated) for the half year ended September 30, 2026 with Limited Review Report issued by the Auditors of the Company.

We request you to kindly take the same on record.

Thanking You,
Yours Sincerely,

For, Infinium Pharmachem Limited

KUNJ ANJAYKUMAR DESAI

Digitally signed by KUNJ ANJAYKUMAR DESAI
Date: 2026.11.06 13:13:53 +05'30'

Kunj Desai
Company Secretary & Compliance Officer

Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
Info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

November 06, 2026

TO,
NSE LIMITED
EXCHANGE PLAZA, 5th FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.

SYMBOL: INFINIUM

Sub: Outcome of Board Meeting

Dear Sir/Madam,

This is to inform you under Regulation 30 and any other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. With reference to the captioned subject and in furtherance to our intimation letter dated October 27, 2026, we hereby inform that the Board of Directors of the company at its meeting held today i.e. **Friday, November 06, 2026** inter-alia discussed and approved the following business item(s):

1. Considered and approved Standalone unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2026.
2. Considered and approved Consolidated unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2026.
3. Considered and approved the maintenance of books of accounts and other relevant books and papers of the Company at its Corporate Office, situated at 205, Sigma Prime Complex, Nr. Sardar Patel Statue, Vallabh Vidyanagar, Anand 388120, Gujarat, India,

Kindly note that the meeting of the Board of Directors of the Company commenced at 11:00 a.m. and concluded at 01:10 p.m.

We request you to kindly take the same on record.

Thanking You,
Yours faithfully,

For, Infinium Pharmachem Limited

KUNJ ANJAYKUMAR DESAI

Digitally signed by KUNJ ANJAYKUMAR DESAI
Date: 2026.11.06 13:14:24 +05'30'

Kunj Desai
Company Secretary & Compliance Officer

ASHOK RAJPARA & CO
Chartered Accountants

Independent Auditor's Review Report on Standalone Unaudited Half Yearly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of INFINIUM PHARMACHEM LIMITED ('the Company') for the half year ended September 30, 2026 ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').

2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulations 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of interim Financial Information Performed by the Independent Auditor of the Entity's, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial Information consists of making inquiries, primarily of the Company's person nel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For. ASHOK RAJPARA & CO
CHARTERED ACCOUNTANTS

(ASHOK RAJPARA)
PROPRIETOR
M. No. 100559
FRN No: 153195W
UDIN: 26100559BPOXXH1950
Place: SURAT
Date: 06/11/2026

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS

A/510, Diamond World, Nr. Mini Bazar, Varachha Road, Surat, Gujarat- 395006
Ph. 9824745000 Email: carajpara@gmail.com

Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2026

(Rs. In Lacs)

PARTICULARS	Half- year ended			Year ended
	30.09.2026	31.03.2026	30.09.2025	31.03.2026
	Unaudited	Audited	Unaudited	Audited
INCOME				
Revenue from Operations	**11201.36**	8384.27	**7260.37**	15644.64
Other Income, net	**128.29**	102.68	**38.33**	141.01
TOTAL INCOME	**11329.65**	8486.95	**7298.7**	**15785.65**
EXPENSES				
Cost of Matetrial Consumed	9196.30	6901.89	5675.42	12577.31
Purchases of Traded Goods	0	0	0	0.00
Changes In Inventories of FG., WIP.	59.83	-33.03	-25.3	-58.33
Employee Benefits Expenses	330.34	294.91	268.28	563.19
Financial Cost	67.15	85.56	143.61	229.17
Deprecaition and Amortization Expenses	129.48	127.5	129.78	257.28
Other Expenses	565.36	386.95	478.62	865.57
TOTAL EXPENSES	**10348.46**	7763.78	**6670.41**	**14434.19**
Profit Before eceptional and extraordinary Items	**981.19**	723.17	**628.29**	**1351.46**
Exceptional Items	0	0	0	0.00
Profit Before Taxes	**981.19**	723.17	**628.29**	**1351.46**
Tax Expenses				
(a) Current Tax	243.22	192.84	162.3	355.14
(b) Deffered Tax Liabilities/(Assets)	3.73	(5.11)	2.56	(2.55)
(c) Prior Year Tax Liabilities/(Assets)	0	(2.16)	(0.71)	(2.87)
Profit (Loss) for the period	**734.24**	**537.60**	**464.14**	**1001.74**
Earing per equity share				
(a) Basic	4.71	3.45	2.98	6.43
(b) Dilluted	4.71	3.45	2.98	6.43

Notes For Standalone Financial Results :

1. The above Standalone Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2026 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 06th November, 2026

2. The above Standalone Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2026 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended) and other recongnised accounting practices and policies, as applicable.

3. The Company operates only in one busines segment viz " Intermediate Chemicals". Accordingly there are no separate reporting segments as per Ind AS 108 " segment reporting".

4. Previous year's/period's figure have been regrouped/rearranged/reclassified wherever necessary, to make them comparable with the figures of the current period.

5. In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been reviewed by the Statutory Auditors of the Company

For, INFINIUM PHARMACHEM LTD

INFINIUM PHARMACHEM LIMITED

Sanjay V Patel
Managing Director
DIN No. : 00370715

Place : V V Nagar
Date : 06/11/2026

Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

STATEMENT OF STANDALONE ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2026

(Rs. In Lacs)

PARTICULARS	As At 30.09.2026 Unaudited	As At 31.03.2026 Audited
A. ASSETS		
1. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	1995.93	1674.96
(b) Intangible Assets	0.00	0.00
(c) Capital Work in Progress	802.55	730.82
(d) Intangible Assets under development	0	0.00
(e) Non Current Investments	1566.27	1566.27
(f) Deffered Tax assets(Net)	4.25	7.98
(g) Long term Loans and Advances	148.5	148.13
(h) Other Assets	166.22	340.51
Total Non Current Assets	**4683.72**	**4468.67**
2. CURRENT ASSETS		
(a) Inventories	3424.62	3076.37
(b) Financial Assets		
(i) Current Investments	0.00	0.00
(ii) Trade Receivable	4971.25	3122.89
(iii) Cash and Cash Equivalents	2556.10	21.03
(iv) Other Balance With Banks	0	2659.05
(v) Loans and Advances	506.3	665.78
(vi) Other Asstes	168.86	100.97
Total Current Assets	**11627.13**	**9646.09**
TOTAL	**16310.85**	**14114.76**
B. EQUITY AND LIABILITIES		
1. EQUITY		
(a) Equity Share Capital	1558.31	1558.31
(b) Other Equity	10748.8	10014.56
Total Equity	**12,307.11**	**11572.87**
2. LIABILITY		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities	679.92	230.36
(b) Deferred Tax Liabilities	0.00	0.00
(c) Other Non Current Liabilities	0.00	16.87
Total Non Current Liabilities	**679.92**	**247.23**
CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Trade Payables	2071.37	341.09
(1) Total outstanding dues of MSME.	211.82	161.95
(2) Total outstanding dues Otherthan MSME.	1859.55	179.14
(ii) Other Financial Liabilities	729.05	1274.91
(b) Other Current Liabilities	21.76	18.23
(c) Provisions	258.42	305.29
(d) Income tax Liabilities	243.22	355.14
Total Current Liabilities	**3323.82**	**2294.66**
TOTAL	**16310.85**	**14114.76**

See Accompanying notes to the Financials results

For, INFINIUM PHARMACHEM LTD

INFINIUM PHARMACHEM LIMITED

Sanjay V Patel
Managing Director
DIN No. : 00370715

Place : V V Nagar
Date : 06/11/2026

Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2026

(Rs. In Lacs)

Particulars	As At 30.09.2026 Unaudited	As At 30.09.2025 Unaudited
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before Tax	981.19	628.29
Adjustments for :		
Depreciation and Amortization	129.48	129.78
Financial Cost	67.15	143.61
Interest Received	(7.69)	(5.60)
Other Non Operating income	0.00	0.00
Operating Profit before working capital changes	**1170.13**	**896.08**
Adjustments for (increase)/Decrease in operating assets :		
Trade Receivable	(1848.36)	(891.58)
Invetories	(348.25)	(1461.72)
Loans and Advances	159.48	(0.60)
Other Current Assets	(67.89)	1565.81
Adjustments for increase/(Decrease) in operating liabilities :		
Trade Payable	1730.28	292.54
Other Current Liabilities	3.53	14.36
Provisions	(158.79)	(176.01)
Increase / (Decrease) in Non Current Assets	0.00	0.00
Cash Generated From Operations	**640.13**	**238.88**
Direct Tax	(243.22)	(161.59)
Net Cash From Operating Activities (A)	**396.91**	**77.29**
B. Cash Flow from Investing Activities		
Purchase of Tangible Fixed Assets (Gross)	(522.18)	(430.93)
Purchase of Intangible Fixed Assets (Gross)	0.00	0.00
Increase / (Decrease) in Non Current Assets	0.00	0.00
Long term Loans and Advances	(0.37)	0.00
Other Non Current Assets	174.29	217.66
Other Non Current Investments	0.00	0.00
Interest Received	7.69	5.60
Other Non Operating income	0.00	0.00
Net Cash used in Investing Activities (B)	**(340.57)**	**(207.67)**
C. Cash Flow from Financing Activities		
Proceeds from Issuing share	0.00	0.00
Share Premium Utilised in W/off IPO Expenses	0.00	0.00
Interest /Finacial Charges Paid	(67.15)	(143.61)
Non Current Laibilities	432.69	412.75
Other Financial Liabilities- Current	(545.86)	(2198.61)
Net Cash used in Financing Activities (c)	**(180.32)**	**(1929.47)**
Net Increase / (Decrease) in cash and cash equivalents (A+B+C)	**(123.98)**	**(2059.85)**
Cash and cash equivalents at the beginning of the year	**2680.08**	**3328.86**
Cash and cash equivalents at the end of the year	**2556.10**	**1269.01**

See Accompanying notes to the Financials results

For, INFINIUM PHARMACHEM LTD

INFINIUM PHARMACHEM LIMITED

Sanjay V Patel
Managing Director
DIN No. : 00370715

Place : V V Nagar
Date : 06/11/2026

ASHOK RAJPARA & CO
Chartered Accountants

Independent Auditor's Review Report on Consolidated Unaudited Half Yearly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **INFINIUM PHARMACHEM LIMITED** ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary constitute "the Group") for the half year ended September 30, 2026 ('the Statement'), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').

2. This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulations 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of interim Financial Information Performed by the Independent Auditor of the Entity's, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial Information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:

   i. Shanghai Tajilin Industrial Co Ltd. - China
   ii. Infinium Green Energy Private Limited - India
   iii. Infinium Healthcare Private Limited - India

5. The consolidated Unaudited Financial Results include the interim financial information of one subsidiary which has not been reviewed by us and whose interim financial information reflects total revenue of Rs. 2443.63 Lacs, total net profit after tax of Rs. 253.26 Lacs for the half year ended September 30, 2026, which have been prepared by Independent CPA as per IFRS and approved by the Management.

A/510, Diamond World, Nr. Mini Bazar, Varachha Road, Surat, Gujarat-395006
Ph. 9824745000 Email: carajpara@gmail.com

ASHOK RAJPARA & CO.
M.No. 100553
CHARTERED ACCOUNTANTS

Our conclusion on the Statement is not modified in respect of the above matter.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For. ASHOK RAJPARA & CO
CHARTERED ACCOUNTANTS

(ASHOK RAJPARA)
PROPRIETOR
M. No. 100559
FRN No: 153195W
UDIN: 26100559TEJFFT1396
Place: SURAT
Date: 06/11/2026

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS

Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2026

(Rs. In Lacs)

PARTICULARS	Half- year ended			Year ended
	30.09.2026	31.03.2026	30.09.2025	31.03.2026
	Unaudited	Audited	Unaudited	Audited
INCOME				
Revenue from Operations	12972.00	10558.09	8405.08	18963.17
Other Income, net	132.94	113.79	100.00	213.79
TOTAL INCOME	**13104.94**	**10671.88**	**8505.08**	**19176.96**
EXPENSES				
Cost of Matetrial Consumed	9492.04	6332.99	6364.63	12697.62
Purchases of Traded Goods	881.88	2095.14	0.00	2095.14
Changes In Inventories of FG., WIP.	(55.42)	73.40	(11.53)	61.87
Employee Benefits Expenses	502.04	468.07	399.27	867.34
Financial Cost	84.99	124.01	156.19	280.20
Deprecaition and Amortization Expenses	147.18	150.92	155.17	306.09
Other Expenses	751.34	476.36	608.31	1084.67
TOTAL EXPENSES	**11804.05**	**9720.88**	**7672.05**	**17392.93**
Profit Before Exceptional & Extraordinary Items	1300.89	951.00	**833.03**	**1784.03**
Exceptional Items	0.00	0.00	0.00	0.00
Profit Before Taxes	**1300.89**	**951.00**	**833.03**	**1784.03**
Tax Expenses				
(a) Current Tax	251.60	195.59	180.02	375.61
(b) Deffered Tax Liabilities/(Assets)	4.55	(10.56)	1.32	(9.24)
(c) Prior Year Tax Liabilities/(Assets)	0.00	(1.73)	(0.53)	(2.26)
Profit after tax for the year	**1044.74**	**767.70**	**652.22**	**1419.92**
Less : Non Controlling Interest	152.14	112.75	92.16	204.91
Profit (Loss) for the period	**892.59**	**654.95**	**560.06**	**1215.01**
Earing per equity share				
(a) Basic	5.73	4.20	3.59	7.80
(b) Dilluted	5.73	4.20	3.59	7.80

Notes For Consolidated Financial Results :

1. The above Consolidated Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2026 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 06th Novermber, 2026

2. The above Consolidated Financial Results of Infinium Pharmachem Limited for the half year ended on 30th September 2026 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended) and other recongnised accounting practices and policies, as applicable.

3. The following subsidiary companies have been considered in the preparation of consolidated financial statements for the half year ended on 30th September, 2026

Name of the entity	Country Of Incorporation	% Of Holding
Shanghai Tajilin Industrial Co. Limited	China	51%
Infinium Green Energy Private Limited	India	51%
Infinium Healthcare Private Limited	India	51%

4. The Company operates only in one business segment viz "Intermediate Chemicals"

5. Previous year's/period's figure have been regrouped/rearranged/reclassified wherever necessary, to make them comparable with the figures ofthe current period."

6. In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been reviewed by the Statutory Auditors of the Company

For, INFINIUM PHARMACHEM LTD

INFINIUM PHARMACHEM LIMITED

Sanjay V Patel
Managing Director
DIN No. : 00370715

Place : V V Nagar
Date : 06/11/2026

Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES FOR HALF YEAR ENDED ON 30TH SEPTEMBER 2026

(Rs. In Lacs)

PARTICULARS	For the half year ended on 30th September, 2026 Unaudited	For the year ended on 31st March,2026 Audited
A. ASSETS		
I. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	2331.86	2007.53
(b) Intangible Assets	0.00	0.00
(c) Capital Work in Progress	887.54	815.81
(d) Intangible Assets : goodwill	339.45	339.45
(e) Non Current Investments	2902.48	2902.48
(f) Deffered Tax assets(Net)	21.30	24.15
(g) Long term Loans and Advances	62.60	61.84
(h) Other Assets	166.22	342.51
Total Non Current Assets	**6711.45**	**6493.77**
2. CURRENT ASSETS		
(a) Inventories	4250.18	3905.21
(b) Financial Assets	0.00	
(i) Current Investments	0.00	0.00
(ii) Trade Receivable	4850.43	3146.16
(iii) Cash and Cash Equivalents	3088.14	299.84
(iv) Other Balance With Banks	0.00	2678.21
(v) Loans and Advances	595.03	683.76
(vi) Other Asstes	453.32	286.65
Total Current Assets	**13237.10**	**10999.83**
TOTAL	**19948.55**	**17493.60**
B. EQUITY AND LIABILITIES		
1. EQUITY		
(a) Equity Share Capital	1558.31	1558.31
(b) Other Equity	11504.46	10546.39
	13062.78	12104.70
(c) Non Controlling Interest	1886.14	1740.81
Total Equity	**14948.91**	**13845.51**
2. LIABILITY		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities	1189.22	763.85
(b) Deferred Tax Liabilities	0.00	0.00
(c) Other Non Current Liabilities	0.00	16.87
Total Non Current Liabilities	**1189.22**	**780.72**
CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Trade Payables	2139.66	407.25
(ii) Other Financial Liabilities	790.18	1521.64
(b) Other Current Liabilities	307.26	234.26
(c) Provisions	292.50	340.22
(d) Income tax Liabilities	280.82	364.00
Total Current Liabilities	**3810.41**	**2867.37**
TOTAL	**19948.55**	**17493.60**

See Accompanying notes to the Financials results

For, INFINIUM PHARMACHEM LTD

Sanjay V Patel
Managing Director
DIN No. 00870715

INFINIUM PHARMACHEM LIMITED

Place : V V Nagar
Date : 06/11/2026

Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2026

(Rs. In Lacs)

Particular	For the half year ended on 30th September, 2026 Unaudited	For the half year ended on 30th September, 2025 Unaudited
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before Tax	**1,300.89**	**833.03**
Adjustments for :		
Depreciation and Amortization	147.18	155.17
Financial Cost	84.99	156.19
Interest Received	0.00	0.00
Other Adjustment non cash items -currency flucuation rereseve	63.78	(25.29)
Non Controlling Interest	(152.14)	(92.16)
Other Non Operating income		
Operating Profit before working capital changes	1444.70	1026.94
Adjustments for (increase)/Decrease in operating assets :		
Trade Receivable	(1704.27)	(1131.01)
Invetories	(344.97)	(1572.46)
Loans and Advances	88.73	28.52
Other Current Assets	(166.67)	1661.39
Adjustments for increase/(Decrease) in operating liabilities :		
Trade Payable	1732.41	529.52
Other Current Liabilities	73.00	115.32
Provisions	(130.91)	(249.56)
Cash Generated From Operations	**992.02**	**408.66**
Direct Tax	-251.60	-179.49
Indirect Tax	0.00	0.00
Net Cash From Operating Activities (A)	**740.42**	**229.17**
B. Cash Flow from Investing Activities		
Purchase of Tangible Fixed Assets (Gross)	(543.24)	(485.67)
Purchase of Intangible Fixed Assets (Gross)	0.00	0.00
Increase / (Decrease) in Non Current Investment	0.00	0.00
Non controlling Interest (BS)	145.33	92.17
Long term Loans and Advances	(0.76)	0.00
Other Non Current Assets	176.29	220.56
Interest Received	0.00	0.00
Other Non Operating income	0.00	0.00
Net Cash used in Investing Activities (B)	**(222.38)**	**(172.94)**
C. Cash Flow from Financing Activities		
Proceeds from Issuing share	0.00	0.00
IPO Expenses W/off	0.00	0.00
Interest /Finacial Charges Paid	(84.99)	(156.19)
Non Current Laibilities	408.50	374.56
Other Financial Liabilities- Current	(731.46)	(2270.09)
Net Cash used in Financing Activities (C)	**(407.95)**	**(2051.72)**
Net Increase / (Decrease) in cash and cash equivalents	**110.09**	**(1995.49)**
Cash and cash equivalents at the beginning of the year	**2978.05**	**3484.00**
Cash and cash equivalents at the end of the year	**3,088.14**	**1,488.51**

See Accompanying notes to the Financials results

For, INFINIUM PHARMACHEM LTD

INFINIUM PHARMACHEM LIMITED

Sanjay V Patel
Managing Director
DIN No. : 00370715

Place : V V Nagar
Date : 06/11/2026